| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_81c02e88b56b9e05dee1fa109004258f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ba3f70d4bcad1958ae8868ddab079b8f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_665df45a169c411f80d2873e91f28e2a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2440-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-154
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-304
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-475 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2013-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1a444b5f2fe538720f37413396cc949
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5d1eeec08c21a5430ac7190babeaf24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afef836d4af8a98159cba174884b2b0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0de1b60ba7fc1c079c73d73d4bcc8dfb |
| publicationDate |
2018-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10059996-B2 |
| titleOfInvention |
Susceptibility to and stratification for monoaminergic antidepressants |
| abstract |
The present invention relates to a method for predicting the non-response or response to a monoaminergic antidepressant of a patient to be treated with a monoaminergic antidepressant comprising the steps: (i) determining the DNA-methylation status of a brain-derived neurotrophic factor (BDNF)-gene promoter in a sample of said patient; (ii) attributing a hypomethylation of said BDNF-gene promoter to the non-response to a monoaminergic antidepressant of said patient; and (iii) attributing normal methylation or hypermethylation of said BDNF-gene promoter to the response to a monoaminergic antidepressant of said patient. Furthermore, a kit and the use of a kit in said method is disclosed. |
| priorityDate |
2012-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |